New Diagnostic Method for Breast and Ovarian Cancer Detection
About 5-10 % of all breast cancers are hereditary, and in 30-40% of these cases a mutation in the BRCA1/2 genes can be detected. The tumor biology of carcinomas with BRCA1 mutation differs significantly from sporadic cancers and cases with BRCA2 mutations involved. It is known that in breast cancer tissue shows a significantly higher T3 receptor (Trijodothyronin receptor, THR) binding capacity as compared to normal breast tissue.
Further Information: PDF
Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0
Contact
Peer Biskup
